Electronic Cigarette blog: explore e-cigarette knowledge, present latest generation of mini e-cigarette, share e-smoking experience and tips, find e-cig sales coupons
1 Current position
Some moves have taken place recently to increase treatment availability in many European countries, and all the licensed NRT products in France, Poland and the United Kingdom are now available over the counter (see Annex 2). The 2-mg gum is already available from herbal drugstores in Poland, and nicotine gum (2-mg and 4-mg), […]
1 Current position
In almost all countries, all NRT products caution that the user should stop smoking when using the product, and most also state that the user should also stop using other sources of nicotine. This advice effectively cautions the smoker against using more than one type of NRT at a time. However, the summary […]
1 Current position
Current product licences indicate that NRT is supposed to be used for a relatively short time, usually coinciding with the first 3 months of the cessation attempt, although there are some inconsistencies between the recommended treatment duration for the different NRT products (see Annex 2). NRT is not intended for indefinite use, during […]
1 Current position
In many countries, smokers are frequently advised to cut down despite the dearth of evidence supporting this as a useful strategy in protecting smokers’ health (35). The use of NRT alongside cutting down has not been recommended, although there is evidence supporting this (see below). In most countries, the current indications for NRT […]
1 Current position
NRT product indications in most countries do not specify use during temporary abstinence from smoking but instead, for relieving withdrawal symptoms as an aid to smoking cessation (see Annex 2).
Most smokers who are prohibited from smoking in certain situations (such as in the workplace, on public transport or in hospital) do not use […]
Smokers has many diseases, cardiovascular is one of them.
1 Current position
All NRT products contain some sort of cautionary statement about their use by people with cardiovascular disease (CVD), and people are usually advised to seek medical advice (see Annex 2). These warnings originated 20 years ago, when NRT was first approved and marketed; at that […]
1 Current position
Again, the advice given for different products for pregnant women (see Annex 2) is inconsistent. For example, in the United Kingdom, some forms of NRT are contraindicated in pregnant women, although the summaries of product characteristics for the sublingual tablet and all the products on general sale (gum, patch, lozenge) state that these […]
3.1 Current position
The advice on the use of various NRT products by young people is inconsistent (see Annex 2). Some of this stems from the different pharmacokinetic properties, and potentially greater risk of abuse, of certain NRT products.
For example, products available in the United Kingdom have the following wordings in the summaries of product characteristics: […]
2.1 Complicating factor of cigarette use Tobacco products are the most dangerous commonly used drug in the WHO European Region. One half of regular smokers will die from cigarettes, and half of these deaths occur prematurely in middle age (ages 35–69 years). Stopping
smoking greatly reduces this risk, and using NRT increases smoking cessation rates. However, […]
In October 1999, the first WHO European Conference on the Regulation of Tobacco Dependence Treatment Products was held in Helsinki, Finland (1). Annex 1 provides a summary of the main conclusions of the Conference.
Following the Conference and other discussions, a paper prepared to take forward some of the issues regarding the regulation of nicotine replacement […]